SYBX — Synlogic Inc
NASDAQ · Healthcare · Biotechnology
$1.22
+$0.01 (+0.62%)
Synlogic Inc (SYBX) is a biotechnology company listed on NASDAQ. It is led by Mary Beth Dooley, based in PO Box 30, Winchester, MA, United States, 01890, with about 1 employees. Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
Latest reported SYBX revenue for 2025-09-30 was $0. Net income was -$2.5M. SYBX currently screens at market cap $14.2M and trailing P/E 5.5.
Use this SYBX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SYBX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SYBX SEC filings page. Lician reads the product cache first so this HTML stays unique to Synlogic Inc even when a live quote feed is slow.
About Synlogic Inc
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
SYBX Key Statistics
Market Cap
$14.16M
Volume
600
Previous Close
$1.18
Day Range
$1.21 – $1.21
P/E Ratio
5.50
EPS
-$1.92
Revenue
$8.00K
Net Income
-$23.36M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-99.8%
Profit Margin
-291987.5%
Employees
1
SYBX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $8.00K | $3.37M | $1.18M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$23.36M | -$61.27M | -$66.15M |
| EPS (Diluted) | -$1.92 | -$9.42 | -$13.83 |
Total Assets
$19.83M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$18.86M
Operating Cash Flow
-$31.66M
Free Cash Flow
$0.00
Synlogic Inc Company Information
- Principal Executive Officer & Principal Financial Officer
- Mary Beth Dooley
- Headquarters
- PO Box 30, Winchester, MA, United States, 01890
- Website
- www.synlogictx.com
- Phone
- 617 659 2802
- IPO / Founded
- 2015-10-01
- Sector
- Healthcare
- Industry
- Biotechnology